Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study

Overview of attention for article published in Drug Safety, January 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 70 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,925 followers.

https://t.co/LdtbruZukC #openaccess #pharmacovigilance #biosimilars #breastcancer @AmgenBiosim

Reply Repost Favourite

RT @Onco_Sean: Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2‑Positive Early Breast Cancer in the Randomized, Doub…

Reply Repost Favourite

Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2‑Positive Early Breast Cancer in the Randomized, Double‑Blind, Active‑Controlled LILAC Study https://t.co/VmWjr3wYMb #CardioOncology @sdent_duke #biosimilars

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.